{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T08:33:56Z","timestamp":1773477236106,"version":"3.50.1"},"reference-count":21,"publisher":"BMJ","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Fam Plann Reprod Health Care"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1783\/147118909788707878","type":"journal-article","created":{"date-parts":[[2009,7,4]],"date-time":"2009-07-04T15:20:18Z","timestamp":1246720818000},"page":"139-142","source":"Crossref","is-referenced-by-count":15,"title":["Qlaira<sup>\u00ae<\/sup>: a \u2018natural\u2019 change of direction"],"prefix":"10.1136","volume":"35","author":[{"given":"Diana","family":"Mansour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2009,7,1]]},"reference":[{"key":"ref_1","first-page":"2","article-title":"A comparative study of the effects of gestodene 60 microg\/ethinylestradiol 15 microg and desogestrel 150 microg\/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolism","volume":"4","author":"van der Mooren MJ; C, Klipping; van Aken B; E, Helmerhorst; D, Spielmann; C, Kluft","year":"1999","unstructured":"van der Mooren MJ, Klipping C, van Aken B, Helmerhorst E, Spielmann D, Kluft C. A comparative study of the effects of gestodene 60 microg\/ethinylestradiol 15 microg and desogestrel 150 microg\/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolism. Eur J Contracept Reprod Health Care 1999; 4(Suppl. 2): 27\u201335.","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"ref_2","first-page":"2","article-title":"The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 microg and ethinylestradiol 15 microg","volume":"4","author":"322, Gestodene Study Group","year":"1999","unstructured":"Gestodene Study Group 322. The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 microg and ethinylestradiol 15 microg. Eur J Contracept Reprod Health Care 1999; 4(Suppl. 2): 9\u201315.","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0378-5122(88)90023-0","article-title":"New natural oestradiol\/cyproterone acetate oral contraceptive for pre-menopausal women","volume":"10","author":"Hirvonen, E.; Stenman, U.H.; M\u00e4lk\u00f6nen, M.; Rasi, V.; Vartiainen, E.; Yl\u00f6stalo, P.","year":"1988","unstructured":"Hirvonen E, Stenman UH, M\u00e4lk\u00f6nen M, Rasi V, Vartiainen E, Yl\u00f6stalo P. New natural oestradiol\/cyproterone acetate oral contraceptive for pre-menopausal women. Maturitas 1988; 10: 201\u2013213.","journal-title":"Maturitas"},{"key":"ref_4","first-page":"183","article-title":"Efficacy and tolerability of a combined oral contraceptive containing 17 beta-estradiol and desogestrel","volume":"1","author":"Kivinen, S.; Saure, A.","year":"1996","unstructured":"Kivinen S, Saure A. Efficacy and tolerability of a combined oral contraceptive containing 17 beta-estradiol and desogestrel. Eur J Contracept Reprod Health Care 1996; 1: 183.","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"ref_5","article-title":"National Agency for Medicines. Femilar tablets: Summary of Product Characteristics [in Finnish]","author":"[3 May 2009].","year":"2007","unstructured":"National Agency for Medicines. Femilar tablets: Summary of Product Characteristics [in Finnish]. 14 May 2007. http:\/\/spc.nam.fi\/indox\/english\/html\/nam\/humspc\/5\/102855.shtml [Accessed 3 May 2009]."},{"key":"ref_6","first-page":"517","article-title":"A 19-norprogestin without 17\u03b2-ethinyl group II: dienogest from a pharmacodynamic point of view","volume":"31","author":"Oettel, M.","year":"1995","unstructured":"Oettel M, Carol W, Elger W, Kaufmann G, Moore C, Romer W, et al. A 19-norprogestin without 17\u03b2-ethinyl group II: dienogest from a pharmacodynamic point of view. Drugs Today 1995; 31: 517\u2013536.","journal-title":"Drugs Today"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/BF03345616","article-title":"Dienogest, a selective progestin, reduces plasma estradiol level through induction of apoptosis of granulosa cells in the ovarian dominant follicle without follicle-stimulating hormone suppression in monkeys","volume":"31","author":"Sasagawa, S.; Shimizu, Y.; Nagaoka, T.; Tokado, H.; Imada, K.; Mizuguchi, K.","year":"2008","unstructured":"Sasagawa S, Shimizu Y, Nagaoka T, Tokado H, Imada K, Mizuguchi K. Dienogest, a selective progestin, reduces plasma estradiol level through induction of apoptosis of granulosa cells in the ovarian dominant follicle without follicle-stimulating hormone suppression in monkeys. J Endocrinol Invest 2008; 31: 636\u2013641.","journal-title":"J Endocrinol Invest"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/09513590009167685","article-title":"Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro","volume":"14","author":"Rabe, T.; Kowald, A.; Ortmann, J.; Rehberger-Schneider, S.","year":"2000","unstructured":"Rabe T, Kowald A, Ortmann J, Rehberger-Schneider S. Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol 2000; 14: 223\u2013230.","journal-title":"Gynecol Endocrinol"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0010-7824(02)00436-5","article-title":"Effect of four different oral contraceptives on various sex hormones and serum-binding globulins","volume":"67","author":"Wiegratz, I.; Kutschera, E.; Lee, J.H.; Moore, C.; Mellinger, U.; Winkler, U.H.","year":"2003","unstructured":"Wiegratz I, Kutschera E, Lee JH, Moore C, Mellinger U, Winkler UH, et al. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception 2003; 67: 25\u201332.","journal-title":"Contraception"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.contraception.2008.10.010","article-title":"Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol\/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol\/2 mg cyproterone acetate","volume":"79","author":"Palombo-Kinne, E.; Schellschmidt, I.; Schumacher, U.; Gr\u00e4ser, T.","year":"2009","unstructured":"Palombo-Kinne E, Schellschmidt I, Schumacher U, Gr\u00e4ser T. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol\/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol\/2 mg cyproterone acetate. Contraception 2009; 79: 282\u2013289.","journal-title":"Contraception"},{"key":"ref_11","first-page":"458","article-title":"Approaches to the replacement of ethinylestradiol by natural 17beta-estradiol in combined oral contraceptives. Exp Toxicol Pathol","volume":"50","author":"Hoffmann, H.; Moore, C.; Zimmermann, H.; Elger, W.; Schwarz, S.; Gr\u00e4ser, T.","year":"1998","unstructured":"Hoffmann H, Moore C, Zimmermann H, Elger W, Schwarz S, Gr\u00e4ser T, et al. Approaches to the replacement of ethinylestradiol by natural 17beta-estradiol in combined oral contraceptives. Exp Toxicol Pathol 1998; 50: 458\u2013464."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.contraception.2008.05.004","article-title":"Ovulation inhibition with four variations of a fourphasic estradiol valerate\/dienogest combined oral contraceptive: results of two prospective, randomized, openlabel studies","volume":"78","author":"Endrikat, J.; Parke, S.; Trummer, D.; Schmidt, W.; Duijkers, I.; Klipping, C.","year":"2008","unstructured":"Endrikat J, Parke S, Trummer D, Schmidt W, Duijkers I, Klipping C. Ovulation inhibition with four variations of a fourphasic estradiol valerate\/dienogest combined oral contraceptive: results of two prospective, randomized, openlabel studies. Contraception 2008; 78: 218\u2013225.","journal-title":"Contraception"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.contraception.2007.01.014","article-title":"Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen","volume":"75","author":"Coffee, A.L.; Sulak, P.J.; Kuehl, T.J.","year":"2007","unstructured":"Coffee AL, Sulak PJ, Kuehl TJ. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 2007; 75: 444\u2013449.","journal-title":"Contraception"},{"key":"ref_14","article-title":"Pharmacokinetics and pharmacodynamics of a new 4-phasic estradiol valerate and dienogest oral contraceptive. Poster presented at the American College of Obstetricians and Gynecologists 55th Annual Meeting","author":"Lu, M.; Uddin, A.; Foegh, M.; Zeun, S.","year":"2007","unstructured":"Lu M, Uddin A, Foegh M, Zeun S. Pharmacokinetics and pharmacodynamics of a new 4-phasic estradiol valerate and dienogest oral contraceptive. Poster presented at the American College of Obstetricians and Gynecologists 55th Annual Meeting, San Diego, CA, USA, May 2007."},{"key":"ref_15","article-title":"Efficacy and tolerability of a new oral contraceptive containing estradiol and dienogest. Poster presented at the American College of Obstetricians and Gynecologists 56th Annual Meeting","author":"Parke, S.; Nahum, G.G.; Wildt, L.; Palacious, S.; Romer, T.; Bitzer, J.","year":"2008","unstructured":"Parke S, Nahum GG, Wildt L, Palacious S, Romer T, Bitzer J. Efficacy and tolerability of a new oral contraceptive containing estradiol and dienogest. Poster presented at the American College of Obstetricians and Gynecologists 56th Annual Meeting, New Orleans, LA, USA, May 2008."},{"key":"ref_16","article-title":"Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a 7-cycle, randomized comparative trial of estradiol valerate\/dienogest and ethinylestradiol\/ levonorgestrel","author":"Ahrendt, H.-J.; Makalova, D.; Parke, S.; Mellinger, U.; Mansour, D.","year":"2009","unstructured":"Ahrendt H-J, Makalova D, Parke S, Mellinger U, Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a 7-cycle, randomized comparative trial of estradiol valerate\/dienogest and ethinylestradiol\/ levonorgestrel. Contraception 2009; (in press).","journal-title":"Contraception"},{"key":"ref_17","article-title":"Metabolic effects of a new 4-phasic combined oral contraceptive containing estradiol valerate and dienogest. Poster presented at the American College of Obstetricians and Gynecologists 56th Annual Meeting","author":"Parke, S.; Nahum, G.G.; Mellinger, U.; Junge, W.","year":"2008","unstructured":"Parke S, Nahum GG, Mellinger U, Junge W. Metabolic effects of a new 4-phasic combined oral contraceptive containing estradiol valerate and dienogest. Poster presented at the American College of Obstetricians and Gynecologists 56th Annual Meeting, New Orleans, LA, USA, May 2008."},{"key":"ref_18","article-title":"Hemostatic effects of a novel four-phasic combined oral contraceptive containing estradiol valerate and dienogest. Poster presented at the European Society of Contraception Biannual Meeting","author":"Klipping, C.; Junge, W.; Mellinger, U.; Duijkers, I.; Parke, S.","year":"2008","unstructured":"Klipping C, Junge W, Mellinger U, Duijkers I, Parke S. Hemostatic effects of a novel four-phasic combined oral contraceptive containing estradiol valerate and dienogest. Poster presented at the European Society of Contraception Biannual Meeting, Prague, Czechoslovakia, April 2008."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(95)91927-9","article-title":"World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease","volume":"346","year":"1995","unstructured":"World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582\u20131588.","journal-title":"Lancet"},{"key":"ref_20","article-title":"Qlaira: Summary of Product Characteristics","author":"plc, Bayer","unstructured":"Bayer plc. Qlaira: Summary of Product Characteristics. http:\/\/emc.medicines.org.uk\/document.aspx?documentId=21700 [Accessed 3 May 2009]."},{"key":"ref_21","first-page":"8","article-title":"The Directory of Community Health Services The ideal reference for anyone working in this sector Order on our secure website www. KeywaysPublishing.com or contact: Keyways Publishing, PO Box 100, Chichester","volume":"18","unstructured":"The Directory of Community Health Services The ideal reference for anyone working in this sector Order on our secure website www.KeywaysPublishing.com or contact: Keyways Publishing, PO Box 100, Chichester, West Sussex, PO18 8HD, UK Tel: 01243 576444 fax: 01243 576456 email: info@KeywaysPublishing.com","journal-title":"West Sussex"}],"container-title":["Journal of Family Planning and Reproductive Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1783\/147118909788707878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T19:47:22Z","timestamp":1757101642000},"score":1,"resource":{"primary":{"URL":"https:\/\/jfprhc.bmj.com\/lookup\/doi\/10.1783\/147118909788707878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2009,7,1]]},"published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.1783\/147118909788707878"],"URL":"https:\/\/doi.org\/10.1783\/147118909788707878","relation":{},"ISSN":["1471-1893","2045-2098"],"issn-type":[{"value":"1471-1893","type":"print"},{"value":"2045-2098","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}